ArticleEBioMedicine2026
Identification of circulatory neuro-related proteins in Parkinson's disease: an integrated genetic-proteomic-clinical study.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuro-related proteins are promising biomarkers and therapeutic targets for Parkinson's disease (PD), yet their specific roles remain uncertain.
methodsWe conducted Mendelian randomisation by integrating protein quantitative trait loci with genome-wide association study data from 33,647 patients with PD and 449,056 controls for risk, 28,568 patients for age at onset (AAO), and 4093 patients for progression. Subsequent analyses included genetic colocalisation, protein-protein interaction, functional enrichment, tissue and cell-specific expression profiling, and druggability assessment. In an case-control study (30 patients with PD, 14 controls), plasma neuro-related proteins were measured using the Olink platform.
findings59 neuro-related proteins were associated with PD: 4 (CLEC1B, IL5RA, SNCG, CDH17) associated with risk, 7 with AAO, and 58 with progression. Colocalisation supported shared variants for TDGF1, PVR, and IL5RA with the progression. 47 proteins were evaluated as druggable targets. Pathway analysis highlighted cytokine-receptor interactions, neuroimmune modulation, and axon guidance. BMP-4, DDR1, GDNF, LAT, and MANF were found to be differentially expressed in patients with PD and correlated with the symptom severity.
interpretationThis integrative genetic-proteomic-clinical framework identifies neuro-related proteins significantly associated with PD, offering mechanistic insights and prioritising therapeutic targets.
fundingNational Natural Science Foundation of China (NO: U24A20694, NO: 82471433), and Scientific Research Foundation of Guangzhou (NO: 202206010005) to QW; and National Natural Science Foundation of China (NO: 82401641) to BD; and Basic and Applied Basic Research of Guangdong (NO: 2025A1515012456) to WLY; and Ministry of Education Academic Research Fund Tier 1 (RG111/24) to JNF; and National Medical Research Council grants to EKT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.